May 31, 2023 · GCC19CART targets guanylate cyclase-C (GCC), which is expressed in the metastatic lesions of 70%-80% of subjects with colorectal cancers and largely restricted to the intestinal tract.

Adults with relapsed and refractory mCRC expressing GCC were treated with GCC19CART, a mixture of autologous CAR T cells transduced with lentiviral vectors expressing genes that encode either CD-19 CAR or GCC CAR.

GCC-CART is human autologous T cells transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting guanylate cyclase 2C (GUCY2C2). GUCY2C2 is a transmembrane protein that is expressed in the metastatic lesions of 70%-80% of subjects with colorectal cancers.

GCC19CART, the first clinical candidate from the CoupledCAR® solid tumor platform, targets guanylate cyclase-C (GCC) which is expressed in colorectal cancers. CoupledCAR utilizes multiple vectors to make both solid tumor targeting CAR-T and CD19 CAR-T in a single manufacturing step.

Nov 5, 2021 · GCC19CART, the first clinical candidate from the CoupledCAR ® solid tumor platform, targets guanylate cyclase-C (GCC) which is expressed in colorectal cancers. A Phase 1 investigator-initiated dose escalation trial is underway in China for patients with relapsed or refractory metastatic colorectal cancer.

GCC19CART targets guanylate cyclase-C (GCC) which is expressed in the metastatic lesions of 70%-80% of subjects with colorectal cancers. A Phase 1 investigator-initiated clinical trial is underway in China for patients with relapsed or refractory metastatic colorectal cancer who have received at least 2 prior lines of therapy.

May 29, 2024 · Guanylate cyclase-C (GCC) has been reported to be expressed in over 80% of colorectal cancers with normal expression largely restricted to the luminal side of the GI tract, making it an appealing target for CAR-T cell therapy.

Jan 25, 2025 · GCC19CART showed significant antitumor activity in refractory mCRC, with a 56% overall response rate across two dose levels. Dose level 2 demonstrated higher efficacy, achieving an 80% ORR and a...

Sep 23, 2024 · The guanylyl cyclase C (GCC)– and CD19-directed autologous CAR T-cell therapy GCC19CART was safe and tolerable, and it showed signs of clinical activity in patients with relapsed/refractory ...

Sep 1, 2021 · Based on ICT’s proprietary solid tumor CoupledCAR ® technology platform, GCC19CART is a CAR T-cell therapy intended to treat refractory or relapsed metastatic colorectal cancer that expresses the target antigen guanylate cyclase 2C (GCC or GUCY2C). GCC-CART has already demonstrated encouraging results in proof-of-concept human trials in China.